# Efficacy of \[18F\]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis

Study · id `cardio:ct-nct05184088` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05184088](<https://clinicaltrials.gov/study/NCT05184088>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05184088

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 244 participants.

## Technical summary

Registry record NCT05184088. Allocation not applicable; no masking; primary purpose diagnostic. Start 2023-01-13 (actual); primary completion 2026-04-21 (actual). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose diagnostic
- Phase: Phase 3
- Enrolled: 244 participants (enrolled count; ClinicalTrials.gov record NCT05184088, source copy `cardio:ctgov-nct05184088-2026-10-26`, retrieved 2026-10-31)
- Started: 2023-01-13 (actual) (ClinicalTrials.gov record NCT05184088, source copy `cardio:ctgov-nct05184088-2026-10-26`, retrieved 2026-10-31)
- Primary completion: 2026-04-21 (actual) (ClinicalTrials.gov record NCT05184088, source copy `cardio:ctgov-nct05184088-2026-10-26`, retrieved 2026-10-31)
- Completion: 2026-05-05 (actual) (ClinicalTrials.gov record NCT05184088, source copy `cardio:ctgov-nct05184088-2026-10-26`, retrieved 2026-10-31)
- Countries: United States; Germany; Spain; United Kingdom (ClinicalTrials.gov record NCT05184088, source copy `cardio:ctgov-nct05184088-2026-10-26`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05184088-2026-10-26`, retrieved 2026-10-31)

## The registry's words

- Brief title: Efficacy of \[18F\]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis
- Acronym: CArdiag
- Condition: Cardiac Amyloidosis
- Condition: AL Amyloidosis
- Condition: ATTR Amyloidosis
- Intervention (Drug): \[18F\]florbetaben
- Lead sponsor: Lantheus Germany GmbH
- Lead sponsor class: INDUSTRY
- Collaborator: pharmtrace klinische Entwicklung GmbH
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Cardiac amyloidosis (`cardio:cardiac-amyloidosis`)

## Provenance

Content hash: ee456643bc9517a64ee8d238fa988e1ebae93384b459fc09205f533372a0b456
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
